基于舞蹈的非药物治疗化疗效应推进途径(DAANCE):多中心随机对照试验研究方案
该多中心前瞻性随机对照试验拟在化疗诱导的周围神经病变(CIN)乳腺癌生存者中,比较改编阿根廷探戈与标准治疗对感觉患者报告结局、功能临床指标及潜在机制的影响。受试者按1:1随机分配至探戈组或标准治疗主动对照组,主要结局为基线至4周干预后感觉患者报告结局的变化。作者假设4周探戈练习在改善感觉和功能方面优于标准治疗。
要点
- 纳入伴有CIN和平衡功能障碍的乳腺癌生存者,随机比较探戈与标准治疗。
- 主要结局为基线至4周感觉患者报告结局的变化,采用线性混合模型分析。
- 探戈剂量为每次10-35分钟、每周不超过2次,原文未写明总干预周数以外的频次细节。
核心结论
- 作者假设4周探戈练习在改善CIN乳腺癌生存者的感觉和功能方面优于标准治疗。
- 作者认为研究结果可能带来一种改善CIN相关缺陷的安全非药物干预。
研究设计与样本
- 多中心、前瞻性、随机对照临床试验,设可选单向外交叉至干预。
- 受试者按1:1比例随机分配至探戈实验组或标准治疗主动对照组。
- 主要结局为基线至4周干预后感觉患者报告结局的变化,采用线性混合模型分析。
- 主要估计目标为两组间基线至第4周主要结局平均变化值的差异。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 主要结局:基线至4周干预后感觉患者报告结局的变化。
- 次要结局包括疲劳等其他患者报告结局,以及干预4周、8周和干预完成后1个月的双任务、平衡、步态和上肢功能临床指标。
- 探索性指标包括姿势控制、步态稳定性、认知负荷和血液生物标志物浓度。
- 探戈剂量为每次10-35分钟、每周不超过2次。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer (BC) is among the most common forms of cancer, particularly among women. Chemotherapies that are most effective in treating BC are known to cause chemotherapy-induced neuropathy (CIN), thus leaving survivors with sensory deficits including pain, numbness, and tingling in the extremities; functional deficits such as impaired neuromotor control and motor-cognitive integration; reduced quality of life; and increased fall risk. Current pharmacologic treatments show limited efficacy and create additional unwanted side effects. In the absence of pharmacologic options, physical activity (PA) has emerged as a promising nonpharmacologic candidate for managing CIN symptoms. The purpose of this trial is to evaluate the effect of Adapted Argentine Tango (Tango) as a potential PA-based treatment for CIN. Toward this end, we will assess the intervention effect of Tango vs. the standard of care (SOC) on patient-reported outcomes of sensation, clinically-relevant measures of function, and potential mechanisms of action. We hypothesize that 4 weeks of Tango practice will improve sensation and function more than SOC among BC survivors with CIN and demonstrated balance dysfunction. METHODS: In a multi-center, prospective, randomized controlled clinical trial with optional one-way crossover to intervention, participants are randomly assigned (1:1 ratio) to the Tango experimental or the SOC active control arms. The primary outcome is measured from baseline to after 4 weeks of intervention in patient-reported outcomes (PROs) of sensation. Secondary outcomes include additional PROs, such as fatigue, and clinical measures of interest including dual-task, balance, gait, and upper extremity function after 4 and 8 weeks of intervention and 1 month following intervention completion. Exploratory measures include postural control, gait stability, cognitive load, and blood-based biomarker concentrations. Linear mixed models will be used to model changes in measured outcomes. The primary estimand will be the difference in mean change in primary outcome from baseline to week 4 between treatment groups. DISCUSSION: The scientific premise of this study is that Tango, at a dose of 10-35 min performed no more than 2× per week, stands to improve CIN symptoms significantly more than the current standard of care by combining PA with auditory-motor entrainment and social engagement. Our findings may lead to a safe non-pharmacologic intervention that improves CIN-related deficits. TRIAL REGISTRATION: This trial was first posted on 12/27/24, which was before enrollment of the first participant on 03/25/25, at ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06749210 under the identifier NCT06749210.
引用
- Luciani BD, Alwan A, Carlson M, et al. Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): study protocol for a multi-center, randomized controlled trial. Trials. 2026. PMID: 41723535. doi:10.1186/s13063-026-09486-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。